Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Winitthana, Thidarat ^a   Lawanprasert, Somsong ^a   Chanvorachote, Pithi ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; NERVE CELL ADHESION MOLECULE; RAC1 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRICLOSAN; UVOMORULIN; VIMENTIN; CADHERIN;

ANOIKIS; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MEMBRANE RESISTANCE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; METASTASIS POTENTIAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PSEUDOPODIUM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANOIKIS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PSEUDOPODIA; SIGNAL TRANSDUCTION; TRICLOSAN; VIMENTIN;

EID: 84908028264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110851     Document Type: Article

References (59)

1. Jones RD, Jampani HB, Newman JL, Lee AS (2000) Triclosan: A review of effectiveness and safety in health care settings. American Journal of Infection Control 28: 184-196.
2. Rodricks JV, Swenberg JA, Borzelleca JF, Maronpot RR, Shipp AM (2010) Triclosan: A critical review of the experimental data and development of margins of safety for consumer products. Critical Reviews in Toxicology 40: 422-484.
3. Fang JL, Stingley RL, Beland FA, Harrouk W, Lumpkins DL, et al. (2010) Occurrence, efficacy, metabolism, and toxicity of triclosan. Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews 28: 147-171.
4. Henry ND, Fair PA (2013) Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid. Journal of Applied Toxicology 33: 265-272.
5. Dayan AD (2007) Risk assessment of triclosan in human breast milk. Food and Chemical Toxicology 45: 125-129.
6. Ciniglia C, Cascone C, Giudice RL, Pinto G, Pollio A (2005) Application of methods for assessing the geno- and cytotoxicity of Triclosan to C. ehrenbergii. Journal of Hazardous Materials 122: 227-232.
7. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR (2008) Cadherin switching. Journal of Cell Science 121: 727-735.
8. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research 68: 3645-3654.
9. Shi Y, Wu H, Zhang M, Ding L, Meng F, et al. (2013) Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagnostic Pathology 8: 1-8.
10. Chunhacha P, Sriuranpong V, Chanvorachote P (2013) Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells. Oncology Letters 5: 1043-1047.
11. Nurwidya F, Takahashi F, Murakami A, Takahashi K (2012) Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Research and Treatment 44: 151-156.
12. Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta - Reviews on Cancer 1796: 75-90.
13. Klymkowsky MW, Savagner P (2009) Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. American Journal of Pathology 174: 1588-1593.
14. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H (2012) Anoikis resistance: An essential prerequisite for tumor metastasis. International Journal of Cell Biology 2012: 1-11.
15. Guadamillas MC, Cerezo A, del Pozo MA (2011) Overcoming anoikis - pathways to anchorageindependent growth in cancer. Journal of Cell Science 124: 3189-3197.
16. Chunhacha P, Chanvorachote P (2012) Roles of caveolin-1 on anoikis resistance in non small cell lung cancer. International Journal of Physiology, Pathophysiology and Pharmacology 4: 149-155.
17. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P (2012) Anoikis: An emerging hallmark in health and diseases. Journal of Pathology 226: 380-393.
18. Chiarugi P, Giannoni E (2008) Anoikis: A necessary death program for anchorage-dependent cells. Biochemical Pharmacology 76: 1352-1364.
19. Liberko M, Kolostova K, Bobek V (2013) Essentials of circulating tumor cells for clinical research and practice. Critical Reviews in Oncology/Hematology 88: 338-356.
20. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, et al. (2011) Circulating tumor cells: Advances in detection methods, biological issues, and clinical relevance. Journal of Cancer Research and Clinical Oncology 137: 1151-1173.
21. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters 253: 180-204.
22. Franco R, Cantile M, Marino FZ, Pirozzi G (2012) Circulating tumor cells as emerging tumor biomarkers in lung cancer. Journal of Thoracic Disease 4: 438-439.
23. Gorges TM, Pantel K (2013) Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunology, Immunotherapy 62: 931-939.
24. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, et al. (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76: 19-25.
25. Hou JM, Krebs M, Ward T, Sloane R, Priest L, et al. (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. American Journal of Pathology 178: 989-996.
26. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, et al. (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 9: 997-1007.
27. Barriere G, Tartary M, Rigaud M (2012) Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012: 382010.
28. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331: 1559-1564.
29. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.
30. Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, et al. (2012) TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. Journal of Biochemistry 151: 205-216.
31. Cheng J-C, Auersperg N, Leung PCK (2012) EGF-Induced EMT and Invasiveness in Serous Borderline Ovarian Tumor Cells: A Possible Step in the Transition to Low-Grade Serous Carcinoma Cells? PLoS ONE 7: e34071.
32. Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, et al. (2013) Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J Biol Chem 288: 1469-1479.
33. Wang ZL, Fan ZQ, Jiang HD, Qu JM (2013) Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 34: 638-646.
34. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, et al. (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226.
35. Ding SZ, Yang YX, Li XL, Michelli-Rivera A, Han SY, et al. (2013) Epithelial-mesenchymal transition during oncogenic transformation induced by hexavalent chromium involves reactive oxygen species-dependent mechanism in lung epithelial cells. Toxicology and Applied Pharmacology 269: 61-71.
36. Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, et al. (2012) WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Laboratory Investigation 92: 371-383.
37. Khongmanee A, Lirdprapamongkol K, Tit-oon P, Chokchaichamnankit D, Svasti J, et al. (2013) Proteomic analysis reveals important role of 14-3-3sigma in anoikis resistance of cholangiocarcinoma cells. Proteomics 13: 3157-3166.
38. Koleske AJ, Baltimore D, Lisanti MP (1995) Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America 92: 1381-1385.
39. Kowitdamrong A, Chanvorachote P, Sritularak B, Pongrakhananon V (2013) Moscatilin Inhibits Lung Cancer Cell Motility and Invasion via Suppression of Endogenous Reactive Oxygen Species. BioMed Research International 2013: 1-11.
40. Zhang Z, Han L, Cao L, Liang X, Liu Y, et al. (2008) Aggregation formation mediated anoikis resistance of BEL7402 hepatoma cells. Folia Histochem Cytobiol 46: 331-336.
41. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, et al. (2004) Snail blocks the cell cycle and confers resistance to cell death. Genes & Development 18: 1131-1143.
42. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis. Cancer cell 22: 725-736.
43. Fidler IJ (2002) The organ microenvironment and cancer metastasis. Differentiation 70: 498-505.
44. Mattila PK, Lappalainen P (2008) Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 9: 446-454.
45. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews Cancer 3: 362-374.
46. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63: 11-30.
47. Herbst RS, Heymach JV, Lippman SM (2008) Lung Cancer. New England Journal of Medicine 359: 1367-1380.
48. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 119: 1420-1428.
49. Ma H, Zheng L, Li Y, Pan S, Hu J, et al. (2013) Triclosan reduces the levels of global DNA methylation in HepG2 cells. Chemosphere 90: 1023-1029.
50. Wang Y, Shang Y (2013) Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Experimental Cell Research 319: 160-169.
51. Hou JM, Krebs M, Ward T, Morris K, Sloane R, et al. (2010) Circulating tumor cells, enumeration and beyond. Cancers 2: 1236-1250.
52. Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48: 365-375.
53. Dauphin M, Barbe C, Lemaire S, Nawrocki-Raby B, Lagonotte E, et al. (2013) Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer 81: 117-122.
54. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 7: 131-142.
55. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Reviews Cancer 7: 415-428.
56. Larsen M, Tremblay ML, Yamada KM (2003) Phosphatases in cell-matrix adhesion and migration. Nat Rev Mol Cell Biol 4: 700-711.
57. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68.
58. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, et al. (2012) The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE 7: 1-15.
59. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews 28: 15-33.